Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Review
2019
Review
2019
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2018
Review
2018
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • figure 2
  • table 1
  • table 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Review
2004
Review
2004
The dipeptide boronic acid analogue VELCADE™ (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
In a phase 2 open‐label study of the novel proteasome inhibitor bortezomib, 54 patients with multiple myeloma who had relapsed… Expand
Is this relevant?